Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BTLC, Ltd. 〉TLC178



TLC178 is our proprietary NanoX formulation of the anticancer drug vinorelbine, developed for the treatment of rhabdomyosarcoma (RMS), a rare form of soft tissue sarcoma that most frequently occurs in children.

Request for Collaboration
 TLC178 is a formulation of vinorelbine loaded into liposomes, designed to reduce toxicity and improve efficacy with fewer administrations.

We are initially developing TLC178 for pediatric RMS. The increased specificity of TLC178 for tumor versus non tumor tissue through the use of our NanoX technology, which utilizes enhanced permeability and retention effects, will enable greater dose intensity, with attendant benefits in antitumor response without impairing the safety profile. TLC178 will have significantly lower myelosuppression, resulting in a lower rate of severe neutropenia. 

In parallel with the pediatric RMS study, we plan to conduct a series of trials evaluating TLC178 in STS and indications for which vinorelbine has been approved, such as non-small cell lung carcinoma.
Rhabdomyosarcoma / soft tissue sarcoma / non-small cell lung carcinoma.
  • Reduced toxicity and the resultant side effects
  • Increase indications
  • Prolonged circulation in blood for passively targeted therapy
People who like this also like
  • Digital Surgical Guide & Artificial Teeth ServiceDigital Surgical Guide & Artificial Teeth Service
  • SNP-810 (OTC)SNP-810 (OTC)
  • Carrier screening for fragile X syndromeCarrier screening for fragile X syndrome
  • Locking Plate SystemLocking Plate System
  • TAH9901 ADHD Trandermal PatchTAH9901 ADHD Trandermal Patch
  • GLP LaboratoriesGLP Laboratories
  • PipelinePipeline
  • SB05SB05
  • PipelinePipeline
  • Medical Image Playing System and MethodMedical Image Playing System and Method